Oct. 19 at 10:33 AM
$RANI I did clearly read the PR. But one thing you'll quickly realized. ANY...I repeat ANY reference to pre-funded warrants is the death knell for any biotech. Trust me, this is NOT my first rodeo with this nonsense. RANI is struggling severely. They already know Rani Pill will never be aapproved in the US. They need cash. So, they ink this deal with Samsara to get cash in the worst deal imaginable. But, just like other biotechs, they cleverly disguise it as a "collaboration" to get a massive number of sheep to chase the stock higher. Roche owns 62% of Chugai but purposely did NOT write the licensing deal.
Important to note Roche ranks #5 by cap in biotech. Chugai is the largest biotech in Japan but ranks #283 by size worldwide.
Case in point.
$MRKR reported a substantial Private Placement on the heels of stellar news with their Apollo study that clearly proves they have a drug that reduces, if not eliminates, Non Hodgkins Lymphoma. That PP was in 12/24 at
$3.20. It's now
$1.X or so.
